OriCell Therapeutics

Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. We have received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.


OriCell Therapeutics has made a large investment in the construction of 4 synergistic innovative product R&D technology platforms. Its long-term development strategy is to focus on the global unmet clinical needs for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer, and develop innovative cellular drugs and bispecific antibodies with high clinical values. Adhering to the vision of "becoming the world-leading developer of novel drugs for tumor immunotherapy", OriCell Therapeutics will continue to explore and make efforts to provide patients and doctors with safer and more effective tumor treatment solutions, and help patients "restore health and reset vitality".

Focus on the development of independent innovation product pipelines

  • At present, 10 independent innovation pipelines for cellular drugs and bispecific antibodies targeting solid tumors have been established. Six products for tumor immunotherapy have entered the stage of clinical development, and two core IND applications are currently underway.
  • We have reached a global development agreement with ANTENGENE (B.6996) regarding our independently developed bispecific antibody, which is worth 142 million USD. Presently, the clinical trial permission for this product has been issued in Australia;
  • The data from the exploratory clinical study on Ori®CAR-001 (Ori®CAR-C101), the first CAR T-cell product targeting liver cancer, have indicated that the product has high safety and development values. This product made its debut at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting;
  • The Ori®TIL-001 project related to the treatment of osteosarcoma was funded by the Science and Technology Commission of Shanghai Municipality. The exploratory clinical study data were released by oral and poster presentations at the 2021 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the 2021 Annual Meeting of the Connective Tissue Oncology Society (CTOS).

Our Journey

2022

June

OriCell Therapeutics reported Phase 1 study data of Ori-CAR017 in oral presentation at ASCO annual meeting 2022


May

OriCell Therapeutics's CAR-T clinical data accepted for presentation at 2022 European Hematology Association 2022 Congress

OriCell selected in Shanghai Professional, Refined, Specialized, Novel Businesses List


April

OriCell CAR-T Product Ori-CAR-017 Clinical Data Abstract Selected for Oral Presentation at ASCO 2022


March

OriCell announced the appointment of Dr. Weidong Cui as Chief Technology Officer

2021

November and October

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting


September 25

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting


September

OriCell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


August

OriCell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


June 7

The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO


June 2

OriCell Therapeutics appointed Emily Tan, a senior expert in the field of strategy and clinical operations, as the company's executive vice president and COO


May

OriCell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2020

December

OriCell Medical received the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets

OriCell Medical established the Shanghai Academician (Expert) Workstation


November

OriCell Medical established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation


October

OriCell Medical won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition


June

OriCell Medical was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

OriCell Medical reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD


2019

December

OriCell Medical received the pre-A round of exclusive funding from Qiming Venture Partners


November

OriCell Medical became a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center

OriCell Medical became one of the funded key technology start-up enterprises in Pudong New Area


April

OriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

2018

November

OriCell Medical was recognized as a High- and New-Technology Enterprise

OriCell Medical received funding from the 2018 Pudong New Area Science and Technology Development Fund

The Secretary-General of the Nobel Prize Committee visited OriCell Medical


October

OriCell Medical attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields


June

OriCell Medical's research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell


May

OriCell Medical signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.


March

The Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"

2017

July

OriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units


May

Shanghai Changzheng Hospital and OriCell Medical joined hands again and established the "Changzheng - OriCell Clinical Research Center" at Shanghai Changzheng Hospital

2016

May

OriCell Medical established the CAR-T technology platform with high memory and high vitality


February

OriCell Medical expanded its R&D team

2015

February

OriCell Medical was founded by OriCell Group; the co-founder Dr. He Xiaowen served as the chief scientist

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

2022

2021

2020

2019

2018

2017

2016

2015

2022

June

OriCell Therapeutics reported Phase 1 study data of Ori-CAR017 in oral presentation at ASCO annual meeting 2022


May

OriCell Therapeutics's CAR-T clinical data accepted for presentation at 2022 European Hematology Association 2022 Congress

OriCell selected in Shanghai Professional, Refined, Specialized, Novel Businesses List


April

OriCell CAR-T Product Ori-CAR-017 Clinical Data Abstract Selected for Oral Presentation at ASCO 2022


March

OriCell announced the appointment of Dr. Weidong Cui as Chief Technology Officer

2021

November and October

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting


September 25

OriCell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for an oral presentation at the 2021 CSCO Annual Meeting


September

OriCell Therapeutics was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


August

OriCell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality


June 7

The first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO


June 2

OriCell Therapeutics appointed Emily Tan, a senior expert in the field of strategy and clinical operations, as the company's executive vice president and COO


May

OriCell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2020

December

OriCell Medical received the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets

OriCell Medical established the Shanghai Academician (Expert) Workstation


November

OriCell Medical established the Pudong New Area Enterprise Postdoctoral Research Workstation Substation


October

OriCell Medical won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition


June

OriCell Medical was the responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

OriCell Medical reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD


2019

December

OriCell Medical received the pre-A round of exclusive funding from Qiming Venture Partners


November

OriCell Medical became a co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center

OriCell Medical became one of the funded key technology start-up enterprises in Pudong New Area


April

OriCell Medical was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality

2018

November

OriCell Medical was recognized as a High- and New-Technology Enterprise

OriCell Medical received funding from the 2018 Pudong New Area Science and Technology Development Fund

The Secretary-General of the Nobel Prize Committee visited OriCell Medical


October

OriCell Medical attended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields


June

OriCell Medical's research results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell


May

OriCell Medical signed a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.


March

The Ministry of Science and Technology approved OriCell Medical as the principal institution to continue and complete the research project of the 973 Program titled "Research on New Intervention Strategies for Ankylosing Spondylitis"

2017

July

OriCell Medical in collaboration with Zhongshan Hospital carried out a series of clinical trials of the cell therapy technologies (among which CAR-T was the most notable) at the Zhongshan-OriCell Therapy Center, which was jointly constructed by the two units


May

Shanghai Changzheng Hospital and OriCell Medical joined hands again and established the "Changzheng - OriCell Clinical Research Center" at Shanghai Changzheng Hospital

2016

May

OriCell Medical established the CAR-T technology platform with high memory and high vitality


February

OriCell Medical expanded its R&D team

2015

February

OriCell Medical was founded by OriCell Group; the co-founder Dr. He Xiaowen served as the chief scientist

Qualifications and Honors

With a strong scientific innovation atmosphere and a team winning numerous awards, we are widely recognized.

  • One of the accredited High- and New-Technology Enterprise in China
  • Co-construction unit of Shanghai Cell Therapy Clinical Transformation Engineering Technology Center
  • The site for Shanghai Academician (Expert) Workstation
  • The site for the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
  • Responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality in 2019 and 2021
  • One of the funded key technology start-up enterprises in Pudong New Area in 2019
  • One of the Shanghai Science and Technology Innovation Companies in 2020
  • Responsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality in 2020 and 2021
  • Won the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition in 2020
  • Having several team members who have gained honorary titles such as Shanghai Chief Technician, Science and Technology Talent of Pudong New Area, and Outstanding Technologist of the 30th Anniversary of Development and Opening of Pudong New Area.

Pudong new area enterprise post-doctoral scientific research workstation

Experts workstation

Shanghai cell therapy clinical engineering technology research

High Tech Business Certification

10th China Innovation & Entrepreneurship Competition Outstanding Business